Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2021 09:15 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

- Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple...
April 26, 2021 09:05 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum

David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon...
February 23, 2021 09:05 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors

- Accomplished executive leader with more than 30 years of experience in finance and operations PHILADELPHIA, PA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON),...
February 12, 2021 15:30 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Announces Closing of Initial Public Offering

PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
January 08, 2021 09:00 ET | Source: Vallon Pharmaceuticals Inc.

Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting

PHILADELPHIA, PA, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc., (“Vallon” or the “Company”), a biopharmaceutical company focused on the development of novel drugs for CNS disorders,...
November 09, 2020 09:00 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR

Results demonstrated that ADAIR had slower absorption and lower early exposure, and was less desirable to recreational drug abusers on key measures of abuse liability compared to commercially...